APC Drug Discovery Platform

Renewable eDC technology applied to antigen target discovery and validation for immunotherapy programs.

What the platform does

The APC drug discovery platform tests whether a candidate antigen is presented, recognized by T cells and functionally relevant, before a program commits to a drug modality.

eDC technology is the cell system: renewable human dendritic cell lines that keep a mature, activated phenotype in culture and accept defined antigens and gene modifications. The platform is the workflow built on that system: antigen configuration, T cell priming, paired target functional assays and controls, reported as antigen- and HLA-dependent evidence.

Why antigen presentation matters

Solid tumor programs depend on finding specific targets. Whatever the modality, the antigen has to be recognized accurately, and for T cell-based approaches that recognition occurs on peptide–HLA complexes. Dendritic cells also take up and spread tumor antigens, which supports responses beyond the first antigen. [13]

Six-step workflow: tumor samples, candidate neoantigens, antigen presentation on eDC, antigen target validation, tumor-specific antigen spread and cancer therapy. Validated antigens inform peptide–HLA-dependent modalities (DC vaccines, mRNA neoantigen vaccines, TCR-T, TIL, antibodies to the peptide–HLA complex) and surface target modalities (CAR-T, BiTE, ADC). Stages 5 and 6 are downstream biology and development beyond the assay. Released tumor antigen is taken up by dendritic cells.
eDC technology in target discovery and validation. Conceptual workflow. Peptide–HLA-dependent modalities, including antibodies to the complex, are tested directly; surface target modalities use the validated antigen list.

Why the eDC platform supports drug discovery

Each row names a bottleneck in antigen-directed discovery, the reason it limits decisions, and what the platform provides.

BottleneckWhy it limits decisionsWhat the platform providesEvidence to request
Prediction is not immunogenicityIn the TESLA consortium, 37 of 608 tested neoantigen candidates (6%) were recognized by T cells. [12]A functional presentation and recognition screen on one APC configurationT cell response per candidate; irrelevant peptide and antigen-negative controls
APC supply varies by donorMoDCs are generated from each donor’s monocytes, so APC quality enters the data as a variable.A renewable line for repeated screens and replicates, with documented passageIdentity, phenotype and viability at the passage used
Recognition is HLA-restrictedA response to a peptide–HLA complex cannot be interpreted without the HLA context.A defined HLA background; paired targets with and without antigen or HLA; HLA blockadeMatched HLA controls and the nonspecific killing background
Complex-specific binders need a validated targetAn antibody, CAR-T, ADC or T cell engager against a peptide–HLA complex can be more specific than one against a surface protein, but only if the complex is immunogenic and presented.Immunogenicity and HLA-dependent recognition of the candidate complex, with antigen-negative and HLA-mismatched controlsT cell response, plus presentation evidence such as immunopeptidomics or recognition of endogenous antigen targets
Immunomodulatory antibodies act on APC receptorsAgonist and checkpoint antibodies need an APC that expresses the target, and their effect shows in APC activation and T cell priming.A mature, activated eDC with costimulatory molecules such as CD40, tested for the intended target before screeningTarget expression on the line used; control antibody matched for isotype and Fc format
Antigen format changes processingPeptide-loaded, gene-encoded and endogenous antigens can be processed differently.eDC expressing the antigen as a gene or fragment, compared with targets expressing the endogenous antigenRecognition of endogenous antigen target cells
APC biology is part of the mechanismCostimulation, cytokines and inhibitory ligands on the APC shape priming.Mature, activated phenotype and APC gene knockout or overexpressionConfirmed modification and a matched control line
One readout is not enoughAcute killing does not establish specificity, breadth or recall.Multi-antigen configurations and serial stimulation within one system, as the design requiresEqual viable effector ratios and scheduled sampling

Workflow

The workflow is the same for a single antigen or a candidate panel. Inputs and acceptance criteria are agreed before work begins.

StageActivityOutput
01 NominateCandidate antigens from tumor sequencing, immunopeptidomics, expression data or prediction, with the relevant HLA typesRanked candidate list and study question
02 ConfigureAntigen-expressing eDC, or custom eDC development from customer PBMCs with agreed gene modificationsCharacterized APC with antigen expression and phenotype
03 PrimeeDC stimulation of responder T cells under defined conditionsT cell populations for each antigen configuration
04 MeasureActivation markers, cytokines, antigen-specific readouts and cytolysis of paired target cells, with HLA blockade and antigen-negative comparisonsAntigen- and HLA-dependent response data with controls
05 DecideCompare candidates by specificity, breadth and recognition of endogenous antigenPrioritized targets for the chosen modality

Binding prediction is one part of the evidence. A candidate is supported when processing, the T cell repertoire, receptor recognition and immune context are considered with it: see neoantigen validation.

Study designs and controls

A useful experiment defines which component the intervention is expected to affect and measures the others as possible confounders.

Study questionEvidence to seekControls that help interpretation
Is a candidate antigen recognized?Peptide–HLA evidence and antigen-specific T cell activity against relevant targetsWild-type or irrelevant antigen, HLA context, APC-only and target-only conditions
Does an APC gene affect priming?Confirmed requested modification, comparable antigen expression and a relevant T cell readoutMatched engineered control, APC viability and comparable culture or passages
Does a compound change the response?Dose- and time-dependent changes in APC state, effector response and functionViability of each component, vehicle controls and separate APC, effector and target exposure when appropriate
Does a biologic, such as an anti-CD40 agonist or a checkpoint antibody, change APC-driven priming?Dose-dependent APC activation (for example CD80, CD86 and IL-12) and priming of T cells against a defined antigenTarget expression confirmed on the line, control antibody matched for isotype and Fc format, stated crosslinking condition, antibody-free eDC
Is a response broad or persistent?Specificity across antigen configurations and functional behavior after repeated challengeMatched input cells, equal viable effector ratios and scheduled sampling
Is a functional result antigen/HLA dependent?Target recognition or cytolysis with comparisons that fit the mechanismAntigen-negative targets, HLA blockade or matched HLA controls, nonspecific killing background
Is the response antigen-specific or allogeneic background?Tetramer-gated antigen-specific T cells, and killing of targets that carry only the defined HLA and antigenMurine fibroblasts expressing the human HLA (for example HLA-A2.1), B2M and the antigen, against the antigen-negative parental line; irrelevant antigen eDC and no-peptide eDC

Candidate peptides, tetramer binding and cytokine release are useful parts of an evidence package, and each answers a different question. Recognition of a target cell expressing the endogenous antigen is particularly valuable when the claim concerns tumor cell recognition.

Representative eDC-stimulated cytolysis data with antigen and HLA controls: hTERT and MAGE-A3.

Which drug modalities benefit

The platform tests antigen presentation and T cell recognition. How directly that evidence applies depends on how the modality recognizes its target.

ModalityRecognizesHow eDC evidence informs the program
DC and mRNA neoantigen vaccinesPeptide–HLA, after presentationDirect. Tests presentation, priming and the breadth of the response.
TCR-T and TCR-based biologicsDefined peptide in a defined HLADirect. Tests antigen and HLA dependence, including against endogenous antigen targets.
TILEndogenous tumor antigensDirect. Identifies which antigens expanded cells recognize.
Antibodies to peptide–HLA complexes, and CAR-T, ADC or T cell engagers built on themA defined peptide–HLA complexDirect for target nomination. eDC work shows whether the complex is immunogenic and recognized in an HLA-dependent way. Presentation on the tumor and binder cross-reactivity still need their own tests.
CAR-T, BiTE, ADC against surface proteinsAccessible cell surface targetIndirect. These modalities bypass peptide–HLA recognition, so eDC work nominates tumor-specific antigens and probes the immune response to them; binders are tested in their own assays.
Immunomodulatory antibodies (for example anti-CD40, anti-PD-L1)A receptor or ligand on the APCDirect. The eDC is the screening cell: compare candidates by APC activation and T cell priming, once target expression is confirmed.

Ways to engage

Each entry point maps to an existing CrossRelay offering. Scope, material requirements and documentation are agreed per project.

Antigen-expressing eDC lines

A defined antigen configuration and HLA context for your own experiments.

Explore eDC lines

Paired assay systems

An eDC component with a paired target cell model for functional assessment.

Explore assay systems

Custom eDC engineering

Customer PBMCs, a defined antigen and agreed genetic modifications, including knockout.

Explore custom projects

Model limits

Interpret results within the model

A coculture does not reproduce trafficking, stromal barriers or the full tumor microenvironment. Findings apply to the tested antigen, HLA context and target cell configuration, and are research evidence rather than a prediction of clinical outcome. A renewable line represents a defined model, not the diversity of donors or tissue DC states. Murine fibroblast targets test recognition of a defined peptide–HLA complex and use mouse antigen processing, so they do not replace human targets expressing the endogenous antigen.

Compare DC research models

Research use only. Customer-specific scope, validation and documentation are defined in the project agreement.

Discuss a discovery project

Antigen list, HLA context, paired targets and the decision the data should support.

Explore scientific support